Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

By SharpBrains | November 7, 2022

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes): Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used…

Read More

Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications

By SharpBrains | August 12, 2020

Neu­rolief wins FDA break­through nod for wear­able neu­ro­mod for depres­sion (Mass Device): Neu­rolief announced today that it received FDA break­through device des­ig­na­tion for its Reliv­ion DP sys­tem for treat­ing major depres­sion. Reliv­ion is a wear­able, non-inva­­sive, mul­ti-chan­nel brain neu­ro­mod­u­la­tion device designed as an adjunc­tive treat­ment to phar­ma­ceu­ti­cal man­age­ment of major depres­sive dis­or­der (MDD) in adults…

Read More

Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare

By SharpBrains | January 4, 2019

Otsu­ka, Click Ther­a­peu­tics part­ner to cre­ate ther­a­py for men­tal ill­ness (Ver­dict Med­ical Devices): “Otsu­ka Pharmaceutical’s US divi­sion Otsu­ka Amer­i­ca has part­nered with Click Ther­a­peu­tics to devel­op and com­mer­cialise a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ing major depres­sive dis­or­der (MDD)

Read More

Transcranial Direct Current Stimulation shows early promise to ameliorate depression, especially if combined with other therapies and dosage optimized

By SharpBrains | October 1, 2018

___ Tran­scra­nial Direct Cur­rent Stim­u­la­tion Promis­ing for Major Depres­sive Dis­or­der (Psy­chi­a­try Advi­sor): “Tran­scra­nial direct cur­rent stim­u­la­tion (tDCS) is an inves­tiga­tive modal­i­ty for major depres­sive dis­or­der (MDD) that has shown some promis­ing results. Though it has a while before it is approved by the US Food and Drug Admin­is­tra­tion, clin­i­cians and patients have been clam­or­ing for…

Read More

FDA clears deep transcranial magnetic stimulation device to treat obsessive-compulsive disorder

By SharpBrains | September 14, 2018

Brain­sWay’s Brain Stim­u­la­tion Device Receives FDA Approval to Treat Obses­­sive-Com­pul­­sive Dis­or­der (IEEE Spec­trum): “In 2013, Jerusalem-based Brain­sWay began mar­ket­ing a new type of brain stim­u­la­tion device that uses mag­net­ic puls­es to treat major depres­sive dis­or­der. Now, thanks to pos­i­tive results in a study of 100 patients, the com­pa­ny has received approval from the U.S. Food…

Read More

Systematic evidence review finds cognitive behavioral therapy as effective as antidepressant medicines in treating depression

By SharpBrains | April 4, 2016 |

Depres­sion: Treat­ment Beyond Med­ica­tion (The Dana Foun­da­tion): “Major depres­sive dis­or­der affects near­ly 7 per­cent of peo­ple in the US aged 18 and up, accord­ing to the Depres­sion and Bipo­lar Sup­port Alliance. Those who seek treat­ment will most like­ly be pre­scribed a sec­ond-gen­er­a­­tion anti­de­pres­sant med­ica­tion such as a selec­tive sero­tonin reup­take inhibitor (SSRI), tri­cyclic anti­de­pres­sant (TCA),…

Read More